The relationship between a firm's patent quality and its market value — The case of US pharmaceutical industry

Abstract This study examined the relationships between corporate market value and four patent quality indicators – relative patent position (RPP), revealed technology advantage (RTA), Herfindahl–Hirschman Index of patents (HHI of patents), and patent citations – in the US pharmaceutical industry. The results showed that RPP and patent citations were positively associated with corporate market value, but HHI of patents was negatively associated with it, while RTA was not significantly related to it. Thus, if pharmaceutical companies want to enhance their market value, they should increase their leading positions in their most important technological fields, cultivate more diversity of technological capabilities, and raise innovative value of their patents. In addition, this study found that market value of pharmaceutical companies with high patent counts was higher than that of pharmaceutical companies with low patent counts, and suggested that pharmaceutical companies with low patent counts should increase RPP in their most technological fields, decrease HHI of patents, or raise patent citations to further enhance their market value. Furthermore, this study developed a classification for the pharmaceutical companies to divide them into four types, and provided some suggestions to them.

[1]  Bronwyn H Hall,et al.  Market value and patent citations , 2005 .

[2]  D. Teece.  Profiting from technological innovation: Implications for integration, collaboration, licensing and public policy , 1993 .

[3]  R. Shortridge,et al.  Market Valuation of Successful Versus Non-Successful R&D Efforts in the Pharmaceutical Industry , 2004 .

[4]  L. G. Soete,et al.  The use of foreign patenting as an internationally comparable science and technology output indicator , 2005, Scientometrics.

[5]  Patrick Sevestre,et al.  The Econometrics of Panel Data , 1993 .

[6]  D. Newbery,et al.  Preemptive Patenting and the Persistence of Monopoly , 1982 .

[7]  Miklós Koren,et al.  Technological Diversification , 2007, SSRN Electronic Journal.

[8]  Laura B. Cardinal,et al.  Internal knowledge generation: the research laboratory and innovative productivity in the pharmaceutical industry , 2000 .

[9]  Chih-Hai Yang,et al.  Innovation and Market Value in Newly-Industrialized Countries: The Case of Taiwanese Electronics Firms , 2003 .

[10]  Klaus Brockhoff,et al.  Competitor technology intelligence in German companies , 1991 .

[11]  Bronwyn H Hall,et al.  Innovation and Market Value , 1998 .

[12]  George Hendrikse,et al.  The Theory of Industrial Organization , 1989 .

[13]  E. Mansfield.  Patents and Innovation: An Empirical Study , 1986 .

[14]  Mark Setterfield,et al.  What is Endogenous Growth Theory , 2007 .

[15]  Anthony F. Breitzman.  Automated identification of technologically similar organizations , 2005, J. Assoc. Inf. Sci. Technol..

[16]  Anthony F. Breitzman,et al.  Technological Powerhouse or Diluted Competence: Techniques for Assessing Mergers Via Patent Analysis , 2002 .

[17]  R. Polk Wagner,et al.  Patent Portfolios , 2005 .

[18]  Kimberly S. Hamilton,et al.  The changing composition of innovative activity in the US -- a portrait based on patent analysis , 2001 .

[19]  Anthony Breitzman,et al.  Using Patent Citation Analysis to Target/Value M&A Candidates , 2002 .

[20]  Megan MacGarvie,et al.  How well do patent citations measure flows of technology? Evidence from French innovation surveys , 2005 .

[21]  Mark Hirschey,et al.  Are Scientific Indicators of Patent Quality Useful to Investors? , 2004 .

[22]  Bronwyn H Hall.  A Note on the Bias in the Herfindahl Based on Count Data , 2000 .

[23]  D. Teece,et al.  Managing Intellectual Capital: Licensing and Cross-Licensing in Semiconductors and Electronics , 1997 .

[24]  Holger Ernst,et al.  Patent portfolios for strategic R & D planning , 1998 .

[25]  C. F. Phillips.  Industrial Market Structure and Economic Performance , 1971 .

[26]  Hsien-che Lai,et al.  Technological Diversification, Complementary Assets, and Performance , 2008 .

[27]  K. Pavitt,et al.  The technological competencies of the world''s largest firms , 1997 .

[28]  Marshall Hall,et al.  Measures of Concentration , 1967 .

[29]  Prabuddha Ganguli.  Global pharmaceutical industry: intellectual wealth and asset protection , 2003, Int. J. Technol. Manag..

[30]  Yongtae Park,et al.  On the Measurement of Patent Stock as Knowledge Indicators , 2006 .

[31]  Mark S. Klock,et al.  The Impact on Intangible Capital on Tobin's q in the Semiconductor Industry , 1993 .

[32]  Cheng Hsiao,et al.  Analysis of Panel Data , 1987 .

[33]  Otto Toivanen,et al.  Innovation and the Market Value of UK Firms, 1989-1995 , 2002 .

[34]  B. Lev,et al.  The capitalization, amortization, and value-relevance of R&D , 1996 .

[35]  Mary O'Mahony,et al.  Productivity, Innovation and Economic Performance , 2000 .

[36]  Elizabeth Garnsey,et al.  A theory of new venture growth , 2002 .

[37]  J. Kasarda,et al.  The State of the Art of Entrepreneurship , 1992 .

[38]  Theodore Sougiannis.  The Accounting Based Valuation of Corporate R&D , 1994 .

[39]  A. Pakes,et al.  The Value of Patents as Indicators of Inventive Activity , 1986 .

[40]  M. Hirschey.  Intangible Capital Aspects of Advertising and R&D Expenditures , 1982 .

[41]  Z. Griliches,et al.  Industry Effects and Appropriability Measures in the Stock Markets Valuation of R&D and Patents , 1987 .

[42]  Jeong-Dong Lee,et al.  An in-depth empirical analysis of patent citation counts using zero-inflated count data model: The case of KIST , 2007, Scientometrics.

[43]  Alok K. Chakrabarti,et al.  The dynamics of innovation : strategic and managerial implications , 2010 .

[44]  Vernon J. Richardson,et al.  Valuation effects of patent quality: A comparison for Japanese and U.S. firms , 2001 .

[45]  M. Trajtenberg.  A Penny for Your Quotes : Patent Citations and the Value of Innovations , 1990 .

[46]  R. Blundell,et al.  Market share, market value and innovation in a panel of British manufacturing firms , 1999 .

[47]  Holger Ernst,et al.  Evaluation of dynamic technological developments by means of patent data , 1999 .

[48]  A. Jaffe.  Technological Opportunity and Spillovers of R&D: Evidence from Firms&Apos; Patents, Profits and Market Value , 1986 .

[49]  Zvi Griliches,et al.  R&D, Patents, and Productivity , 1981 .

[50]  Chung-Jen Chen,et al.  Patent portfolio diversity, technology strategy, and firm value , 2006, IEEE Transactions on Engineering Management.

[51]  F. Scherer,et al.  Patent Statistics as a Measure of Technical Change , 1969, Journal of Political Economy.

[52]  Bronwyn H. Hall,et al.  The Stock Market's Valuation of R&D Investment during the 1980's , 1993 .

[53]  Sadao Nagaoka.  Determinants of high-royalty contracts and the impact of stronger protection of intellectual property rights in Japan , 2005 .

[54]  Elizabeth J. Jensen.  Research Expenditures and the Discovery of New Drugs , 1987 .

[55]  D. Harhoff,et al.  Citation Frequency and the Value of Patented Inventions , 1999, Review of Economics and Statistics.

[56]  Mark Rogers,et al.  Innovation and Performance: Benchmarking Australian Firms , 2003 .

[57]  Bronwyn H. Hall,et al.  The Value of Intangible Corporate Assets: An Empirical Study of the Components of Tobin's Q , 1993 .

[58]  Alok K. Chakrabarti,et al.  Take a Proactive Approach to Negotiating Your R&D Budget , 1997 .

[59]  F. Narin,et al.  Science and Technology as Predictors of Stock Performance , 1999 .

[60]  A. Oliveira,et al.  A new competitive landscape , 2007 .

[61]  Faiz Kermani,et al.  Patent issues and future trends in drug development , 1969 .

[62]  Mark A. Schankerman,et al.  Characteristics of patent litigation: a window on competition , 2001 .

[63]  Holger Ernst,et al.  Patent information for strategic technology management , 2003 .

[64]  M. Trajtenberg,et al.  Patents, Citations and Innovations , 2002 .

[65]  Jerry J. Weygandt,et al.  Amortization Policy For Advertising And Research And Development Expenditures , 1985 .

[66]  W. Greene,et al.  计量经济分析 = Econometric analysis , 2009 .

[67]  M. Arce,et al.  Empirical evidence of the effect of European accounting differences on the stock market valuation of earnings and book value , 2002 .

[68]  O. Granstrand,et al.  Multi-Technology Corporations: Why They Have “Distributed” Rather Than “Distinctive Core” Competencies , 1997 .

[69]  Bart van Looy,et al.  Technological Diversification, Coherence and Performance of Firms , 2007 .

[70]  Chung-Jen Chen,et al.  Patent portfolio diversity, technology strategy, and firm value , 2006, IEEE Trans. Engineering Management.

[71]  M. Hu,et al.  Knowledge flows and innovation capability: The patenting trajectory of Taiwan's thin film transistor-liquid crystal display industry , 2008 .

[72]  G. Mossinghoff,et al.  The importance of intellectual property protection to the American research-intensive pharmaceutical industry , 1996 .

[73]  Vasanthakumar N. Bhat,et al.  Patent term extension strategies in the pharmaceutical industry , 2005 .

[74]  Henry G. Grabowski,et al.  A New Look at the Returns and Risks to Pharmaceutical R&D , 1990 .

[75]  Z. Griliches.  Market Value, R&D, and Patents , 1981 .